Quantification of the median fluorescence intensity of CD3 and CD4 in mycosis fungoides/Sezary syndrome versus non-neoplastic control cases in peripheral blood-Reference-Cited by-同舟云学术

Quantification of the median fluorescence intensity of CD3 and CD4 in mycosis fungoides/Sezary syndrome versus non-neoplastic control cases in peripheral blood

Published:2024-08-02 Issue: Volume: Page:
ISSN:1868-9256
Container-title:Journal of Hematopathology
language:en
Short-container-title:J Hematopathol

Author:

Fei Fei,Brar Nivaz,Herring Melissa Beth,Menke Joshua R.,Oak Jean,Fernandez-Pol Sebastian^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12308-024-00599-2.pdf

Reference15 articles.

1. Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W et al (2021) Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sezary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 100(2):183–191

2. Pulitzer MP, Horna P, Almeida J (2021) Sezary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping. Cytometry B Clin Cytom 100(2):132–138

3. Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France

4. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110(6):1713–1722

5. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR et al (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29(18):2598–2607